Remission of indolent systemic mastocytosis in the absence of targeted therapy.

J Allergy Clin Immunol Pract

Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Electronic address:

Published: August 2022

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378347PMC
http://dx.doi.org/10.1016/j.jaip.2022.02.043DOI Listing

Publication Analysis

Top Keywords

remission indolent
4
indolent systemic
4
systemic mastocytosis
4
mastocytosis absence
4
absence targeted
4
targeted therapy
4
remission
1
systemic
1
mastocytosis
1
absence
1

Similar Publications

Objectives: Granulomatous invasive fungal sinusitis (GIFS) affects immunocompetent individuals. There is ongoing debate over whether surgery, antifungal medication, or a combined approach is the best treatment. This article summarizes reports about GIFS and its management.

View Article and Find Full Text PDF

Waldenström macroglobulinemia (WM) is a rare lymphoproliferative malignancy presenting with para-proteinemia. The symptoms are attributable to both lymphoproliferation and IgM flare. Gastrointestinal manifestations are not uncommon.

View Article and Find Full Text PDF
Article Synopsis
  • Dermatofibrosarcoma protuberans (DFSP) with atrophic and pigmentary features (AP-DFSP) is a rare skin condition characterized by lesions mainly on the trunk and limbs, often presenting as depressed, colored plaques.
  • This study analyzed 14 cases of AP-DFSP to determine clinical features, treatment responses, and prognostic outcomes, finding that patients had a mean age of 25 years and most cases were successfully treated with complete surgical excision.
  • Results indicated that AP-DFSP has more benign characteristics compared to standard DFSP, with a high likelihood of complete remission following surgery and no reported local recurrences or metastasis in the studied cases.
View Article and Find Full Text PDF

Complete skin remission of Sneddon-Wilkinson disease with acalabrutinib.

Australas J Dermatol

November 2024

Sir Peter McCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.

Sneddon-Wilkinson (SW) disease is rare condition which typically occurs in the context of a monoclonal immunoglobulin and treatment options have not been well studied. Here we present a case of a 65-year-old female with SW with underlying, otherwise indolent, lymphoplasmacytic lymphoma (LPL) with an IgA paraprotein, who achieved a complete skin remission with the administration of the Bruton Tyrosine Kinase inhibitor (BTKi), acalabrutinib.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!